Bactiguard Holding AB (publ) (BACTI-B.ST)
SEK 30.6
(5.15%)
SEK 30.6
(5.15%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 139.98 Million SEK | -170.73% |
| 2022 | 180.14 Million SEK | 37.72% |
| 2021 | 130.8 Million SEK | -4.61% |
| 2020 | 137.12 Million SEK | -10.33% |
| 2019 | 152.92 Million SEK | 22.95% |
| 2018 | 124.38 Million SEK | -2.21% |
| 2017 | 127.19 Million SEK | 23.56% |
| 2016 | 102.93 Million SEK | -16.66% |
| 2015 | 123.51 Million SEK | 19.98% |
| 2014 | 102.94 Million SEK | -11.59% |
| 2013 | 116.44 Million SEK | -7.76% |
| 2012 | 126.23 Million SEK | 3004.72% |
| 2011 | 4.06 Million SEK | -96.4% |
| 2010 | 112.95 Million SEK | -8.94% |
| 2009 | 124.04 Million SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q3 | 66.73 Million SEK | 611.55% |
| 2024 Q1 | -17.01 Million SEK | 33.95% |
| 2024 Q2 | -13.04 Million SEK | 23.32% |
| 2023 Q4 | -25.75 Million SEK | -163.99% |
| 2023 FY | -127.41 Million SEK | -170.73% |
| 2023 Q1 | 47.01 Million SEK | 55.2% |
| 2023 Q2 | 26.02 Million SEK | -44.65% |
| 2023 Q3 | 40.25 Million SEK | 54.68% |
| 2022 Q3 | 54.56 Million SEK | 11.33% |
| 2022 Q4 | 30.29 Million SEK | -44.48% |
| 2022 FY | 180.14 Million SEK | 37.72% |
| 2022 Q1 | 46.27 Million SEK | 100.26% |
| 2022 Q2 | 49.01 Million SEK | 5.9% |
| 2021 Q1 | 35.49 Million SEK | 36.72% |
| 2021 Q3 | 35.95 Million SEK | -0.82% |
| 2021 Q4 | 23.11 Million SEK | -35.72% |
| 2021 FY | 130.8 Million SEK | -4.61% |
| 2021 Q2 | 36.24 Million SEK | 2.13% |
| 2020 Q2 | 43.03 Million SEK | -1.34% |
| 2020 Q1 | 43.61 Million SEK | 38.02% |
| 2020 FY | 137.12 Million SEK | -10.33% |
| 2020 Q3 | 24.51 Million SEK | -43.03% |
| 2020 Q4 | 25.96 Million SEK | 5.9% |
| 2019 FY | 152.92 Million SEK | 22.95% |
| 2019 Q4 | 31.6 Million SEK | -47.52% |
| 2019 Q3 | 60.21 Million SEK | 95.8% |
| 2019 Q2 | 30.75 Million SEK | 1.31% |
| 2019 Q1 | 30.35 Million SEK | 40.49% |
| 2018 Q3 | 31.05 Million SEK | -29.91% |
| 2018 Q4 | 21.6 Million SEK | -30.43% |
| 2018 FY | 124.38 Million SEK | -2.21% |
| 2018 Q1 | 27.4 Million SEK | -5.35% |
| 2018 Q2 | 44.31 Million SEK | 61.73% |
| 2017 Q4 | 28.94 Million SEK | -7.08% |
| 2017 Q3 | 31.15 Million SEK | 4.07% |
| 2017 FY | 127.19 Million SEK | 23.56% |
| 2017 Q2 | 29.93 Million SEK | -19.43% |
| 2017 Q1 | 37.15 Million SEK | 94.16% |
| 2016 Q3 | 32.75 Million SEK | 18.59% |
| 2016 Q4 | 19.13 Million SEK | -41.58% |
| 2016 Q1 | 23.42 Million SEK | 98.83% |
| 2016 FY | 102.93 Million SEK | -16.66% |
| 2016 Q2 | 27.62 Million SEK | 17.92% |
| 2015 Q3 | 58.55 Million SEK | 126.54% |
| 2015 Q1 | 27.33 Million SEK | 78.18% |
| 2015 FY | 123.51 Million SEK | 19.98% |
| 2015 Q2 | 25.84 Million SEK | -5.45% |
| 2015 Q4 | 11.78 Million SEK | -79.88% |
| 2014 Q2 | 29.64 Million SEK | -9.88% |
| 2014 Q4 | 15.34 Million SEK | -38.78% |
| 2014 FY | 102.94 Million SEK | -11.59% |
| 2014 Q3 | 25.06 Million SEK | -15.46% |
| 2014 Q1 | 32.89 Million SEK | -16.31% |
| 2013 Q3 | 29.56 Million SEK | 42.39% |
| 2013 Q4 | 39.3 Million SEK | 32.97% |
| 2013 Q1 | 26.81 Million SEK | -3.98% |
| 2013 Q2 | 20.76 Million SEK | -22.57% |
| 2013 FY | 116.44 Million SEK | -7.76% |
| 2012 Q2 | 19.62 Million SEK | 0.0% |
| 2012 FY | 126.23 Million SEK | 3004.72% |
| 2012 Q4 | 27.92 Million SEK | 13.78% |
| 2012 Q3 | 24.54 Million SEK | 25.05% |
| 2011 Q4 | - SEK | 0.0% |
| 2011 FY | 4.06 Million SEK | -96.4% |
| 2010 FY | 112.95 Million SEK | -8.94% |
| 2009 FY | 124.04 Million SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Acarix AB (publ) | 5.29 Million SEK | -2542.647% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 53.433% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 53.433% |
| Arcoma AB | 11.07 Million SEK | -1164.393% |
| BICO Group AB (publ) | 1.83 Billion SEK | 92.353% |
| Boule Diagnostics AB (publ) | 249.71 Million SEK | 43.943% |
| CellaVision AB (publ) | 463.04 Million SEK | 69.769% |
| Clinical Laserthermia Systems AB (publ) | 2.99 Million SEK | -4570.704% |
| Chordate Medical Holding AB (publ) | -28.41 Million SEK | 592.647% |
| C-Rad AB (publ) | 66.01 Million SEK | -112.044% |
| Duearity AB (publ) | -4.17 Million SEK | 3450.431% |
| Dignitana AB (publ) | 58.97 Million SEK | -137.373% |
| Episurf Medical AB (publ) | -41.8 Million SEK | 434.883% |
| Getinge AB (publ) | 13.43 Billion SEK | 98.958% |
| Scandinavian Real Heart AB (Publ) | -50.21 Million SEK | 378.75% |
| Iconovo AB (publ) | 17.57 Million SEK | -696.358% |
| Integrum AB (publ) | 690.56 Thousand SEK | -20170.591% |
| Luxbright AB (publ) | -2.79 Million SEK | 5104.905% |
| Mentice AB (publ) | 236.38 Million SEK | 40.782% |
| OssDsign AB (publ) | 83.64 Million SEK | -67.351% |
| Paxman AB (publ) | 12.61 Million SEK | -1009.375% |
| Promimic AB (publ) | 38.51 Million SEK | -263.445% |
| Qlife Holding AB (publ) | -50.75 Million SEK | 375.808% |
| SciBase Holding AB (publ) | 16.03 Million SEK | -772.863% |
| ScandiDos AB (publ) | 47.55 Million SEK | -194.356% |
| Sectra AB (publ) | 557.55 Million SEK | 74.894% |
| Sedana Medical AB (publ) | 108.98 Million SEK | -28.445% |
| Senzime AB (publ) | 8.33 Million SEK | -1578.631% |
| SpectraCure AB (publ) | -9.22 Million SEK | 1617.738% |
| Stille AB | 132.17 Million SEK | -5.909% |
| Vitrolife AB (publ) | 1.97 Billion SEK | 92.923% |
| Xvivo Perfusion AB (publ) | 416.91 Million SEK | 66.424% |